Skip to main content
Log in

The Clinical and Forensic Toxicology of Z-drugs

  • Review Article
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

The Z-drugs zolpidem, zopiclone, and zaleplon were hailed as the innovative hypnotics of the new millennium, an improvement to traditional benzodiazepines in the management of insomnia. Increasing reports of adverse events including bizarre behavior and falls in the elderly have prompted calls for caution and regulation. Z-drugs have significant hypnotic effects by reducing sleep latency and improving sleep quality, though duration of sleep may not be significantly increased. Z-drugs exert their effects through increased γ-aminobutyric acid (GABA) transmission at the same GABA-type A receptor as benzodiazepines. Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1–7 h). Zopiclone with the longest duration of action has the greatest residual effect, similar to short-acting benzodiazepines. Neuropsychiatric adverse events have been reported with zolpidem including hallucinations, amnesia, and parasomnia. Poisoning with Z-drugs involves predominantly sedation and coma with supportive management being adequate in the majority. Flumazenil has been reported to reverse sedation from all three Z-drugs. Deaths from Z-drugs are rare and more likely to occur with polydrug overdose. Z-drugs can be detected in blood, urine, oral fluid, and postmortem specimens, predominantly with liquid chromatography–mass spectrometry techniques. Zolpidem and zaleplon exhibit significant postmortem redistribution. Zaleplon with its ultra-short half-life has been detected in few clinical or forensic cases possibly due to assay unavailability, low frequency of use, and short window of detection. Though Z-drugs have improved pharmacokinetic profiles, their adverse effects, neuropsychiatric sequelae, and incidence of poisoning and death may prove to be similar to older hypnotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montplaisir J, Hawa R, Moller H et al (2003) Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 18(1):29–38

    Article  PubMed  CAS  Google Scholar 

  2. Stewart R, Besset A, Bebbington P et al (2006) Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 29(11):1391–1397

    PubMed  Google Scholar 

  3. Glass J, Lanctot KL, Herrmann N et al (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331(7526):1169

    Article  PubMed  Google Scholar 

  4. Dolder C, Nelson M, McKinsey J (2007) Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 21(5):389–405

    Article  PubMed  CAS  Google Scholar 

  5. Dang A, Garg A, Rataboli PV (2011) Role of zolpidem in the management of insomnia. CNS Neurosci Ther 17(5):387–397

    Article  PubMed  CAS  Google Scholar 

  6. Wagner J, Wagner ML (2000) Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 4(6):551–581

    Article  PubMed  Google Scholar 

  7. Dolder CR, Nelson MH (2008) Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 22(12):1021–1036

    Article  PubMed  CAS  Google Scholar 

  8. Barbera J, Shapiro C (2005) Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 28(4):301–318

    Article  PubMed  CAS  Google Scholar 

  9. Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8(4):309–325

    Article  PubMed  Google Scholar 

  10. Nutt DJ, Stahl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 24(11):1601–1612

    Article  PubMed  CAS  Google Scholar 

  11. Sanofi-Aventis (2012) Product Information: Stilnox ® CR Modified Release Tablets. http://products.sanofi.com.au/aus_pi_stilnoxCR.pdf Accessed on 1 Dec 2012

  12. Barkin RL (2007) Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 14(3):299–305

    Article  PubMed  Google Scholar 

  13. Holm KJ, Goa KL (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59(4):865–889

    Article  PubMed  CAS  Google Scholar 

  14. Nutt DJ, Feetam CL (2010) What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. J Psychopharmacol 24(8):1137–1141

    Article  PubMed  CAS  Google Scholar 

  15. George CF (2001) Pyrazolopyrimidines. Lancet 358(9293):1623–1626

    Article  PubMed  CAS  Google Scholar 

  16. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43(4):227–238

    Article  PubMed  CAS  Google Scholar 

  17. Greenblatt DJ, Legangneux E, Harmatz JS et al (2006) Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46(12):1469–1480

    Article  PubMed  CAS  Google Scholar 

  18. Halas CJ (2006) Eszopiclone. Am J Health Syst Pharm 63(1):41–48

    Article  PubMed  CAS  Google Scholar 

  19. Najib J (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 28(4):491–516

    Article  PubMed  CAS  Google Scholar 

  20. Staner L, Eriksson M, Cornette F et al (2009) Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 10(6):616–620

    Article  PubMed  CAS  Google Scholar 

  21. US Food & Drug Administration (2013) FDA requires lower recommended doses for certain drugs containing zolpidem http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm Accessed 20 Jan 2013

  22. Brunello N, Bettica P, Amato D et al (2008) Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. Eur Neuropsychopharmacol 18(S4):S581–S582

    Article  Google Scholar 

  23. Fernandez C, Maradeix V, Gimenez F et al (1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21(6):1125–1128

    PubMed  CAS  Google Scholar 

  24. Cienki JJ, Burkhart KK, Donovan JW (2005) Zopiclone overdose responsive to flumazenil. Clin Toxicol (Phila) 43(5):385–386

    Article  Google Scholar 

  25. Yang C-C, Deng J-F (2008) Utility of flumazenil in zopiclone overdose. Clin Toxicol (Phila) 46(9):920–921

    Article  Google Scholar 

  26. Patat A, Naef MM, van Gessel E et al (1994) Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 56(4):430–436

    Article  PubMed  CAS  Google Scholar 

  27. Hojer J, Salmonson H, Sundin P (2002) Zaleplon-induced coma and bluish-green urine: possible antidotal effect by flumazenil. J Toxicol Clin Toxicol 40(5):571–572

    PubMed  Google Scholar 

  28. Olubodun JO, Ochs HR, Truten V et al (2002) Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol 42(10):1142–1146

    Article  PubMed  CAS  Google Scholar 

  29. Hines LE, Murphy JE (2011) Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9(6):364–377

    Article  PubMed  CAS  Google Scholar 

  30. Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17(7):513–532

    Article  PubMed  CAS  Google Scholar 

  31. Hojo Y, Echizenya M, Ohkubo T et al (2011) Drug interaction between St John’s wort and zolpidem in healthy subjects. J Clin Pharm Ther 36(6):711–715

    Article  PubMed  CAS  Google Scholar 

  32. Swainston Harrison T, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19(1):65–89

    Article  PubMed  Google Scholar 

  33. Vlase L, Popa A, Neag M et al (2011) Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol 51(8):1233–1236

    Article  PubMed  CAS  Google Scholar 

  34. Vlase L, Popa A, Neag M et al (2011) Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 35(3–4):83–87

    Article  PubMed  CAS  Google Scholar 

  35. US Food & Drug Administration (2007) FDA Requests Label Change for All Sleep Disorder Drug Products. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108868.htm Accessed 1 Dec 2012

  36. Duggal HS (2007) New-onset transient hallucinations possibly due to eszopiclone: a case study. Prim Care Companion J Clin Psychiatry 9(6):468–469

    Article  PubMed  Google Scholar 

  37. Stone JR, Zorick TS, Tsuang J (2008) Dose-related illusions and hallucinations with zaleplon. Clin Toxicol (Phila) 46(4):344–345

    Article  CAS  Google Scholar 

  38. Tsai MJ, Huang YB, Wu PC (2003) A novel clinical pattern of visual hallucination after zolpidem use. J Toxicol Clin Toxicol 41(6):869–872

    Article  PubMed  Google Scholar 

  39. Elko CJ, Burgess JL, Robertson WO (1998) Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 36(3):195–203

    Article  PubMed  CAS  Google Scholar 

  40. Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(S1):9–15

    Article  PubMed  CAS  Google Scholar 

  41. Hajak G, Muller WE, Wittchen HU et al (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98(10):1371–1378

    Article  PubMed  CAS  Google Scholar 

  42. Chien C-C, Huanga H-T, Lung F-W et al (2011) Zolpidem withdrawal delirium, seizure, and acute psychosis: case reports and literature review. J Subs Use 16(4):330–338

    Article  Google Scholar 

  43. Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13(6):879–893

    Article  PubMed  CAS  Google Scholar 

  44. Victorri-Vigneau C, Dailly E, Veyrac G et al (2007) Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 64(2):198–209

    Article  PubMed  Google Scholar 

  45. Cimolai N (2007) Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53(12):2124–2129

    PubMed  Google Scholar 

  46. Tonon MA, Bonato PS (2012) Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices. Bioanalysis 4(3):291–304

    Article  PubMed  CAS  Google Scholar 

  47. Boniface PJ, Russell SG (1996) Two cases of fatal zopiclone overdose. J Anal Toxicol 20(2):131–133

    Article  PubMed  CAS  Google Scholar 

  48. Han E, Kim E, Hong H et al (2012) Evaluation of postmortem redistribution phenomena for commonly encountered drugs. Forensic Sci Int 219(1–3):265–271

    Article  PubMed  CAS  Google Scholar 

  49. Kintz P, Villain M, Concheiro M et al (2005) Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int 150(2–3):213–220

    Article  PubMed  CAS  Google Scholar 

  50. Leikin JB, Watson WA (2003) Post-mortem toxicology: what the dead can and cannot tell us. J Toxicol Clin Toxicol 41(1):47–56

    Article  PubMed  CAS  Google Scholar 

  51. Levine B (2010) Principles of forensic toxicology. AACC, Washington, DC

    Google Scholar 

  52. Rust KY, Baumgartner MR, Meggiolaro N et al (2012) Detection and validated quantification of 21 benzodiazepines and 3 “z-drugs” in human hair by LC-MS/MS. Forensic Sci Int 215(1–3):64–72

    Article  PubMed  CAS  Google Scholar 

  53. Drover D, Lemmens H, Naidu S et al (2000) Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 22(12):1443–1461

    Article  PubMed  CAS  Google Scholar 

  54. Scott-Ham M, Burton FC (2005) Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 12(4):175–186

    Article  PubMed  Google Scholar 

  55. Bramness JG, Arnestad M, Karinen R et al (2001) Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma. J Forensic Sci 46(5):1247–1249

    PubMed  CAS  Google Scholar 

  56. Garnier R, Guerault E, Muzard D et al (1994) Acute zolpidem poisoning—analysis of 344 cases. J Toxicol Clin Toxicol 32(4):391–404

    Article  PubMed  CAS  Google Scholar 

  57. Gjerde H, Christophersen AS, Normann PT et al (2011) Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006–2008. Forensic Sci Int 212(1–3):102–109

    Article  PubMed  Google Scholar 

  58. Gock SB, Wong SH, Nuwayhid N et al (1999) Acute zolpidem overdose—report of two cases. J Anal Toxicol 23(6):559–562

    Article  PubMed  CAS  Google Scholar 

  59. Jones AW, Holmgren A (2012) Concentrations of zolpidem and zopiclone in venous blood samples from impaired drivers compared with femoral blood from forensic autopsies. Forensic Sci Int 222(1–3):118–123

    Article  PubMed  CAS  Google Scholar 

  60. Sanofi-Aventis (2011) Product monograph: Imovane (zopiclone). http://products.sanofi.ca/en/imovane.pdf Accessed 1 Dec 2012

  61. Takayasu T, Ishida Y, Kimura A et al (2008) Distribution of zolpidem in body fluids and organ tissues in five autopsy cases. Forensic Toxicol 26(2):80–84

    Article  CAS  Google Scholar 

  62. Baselt RC (2004) Disposition of toxic drugs and chemicals in man. Biomedical, Foster

    Google Scholar 

  63. Bosker WM, Huestis MA (2009) Oral fluid testing for drugs of abuse. Clin Chem 55(11):1910–1931

    Article  PubMed  CAS  Google Scholar 

  64. Laloup M, Ramirez Fernandez Mdel M, De Boeck G et al (2005) Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair. J Anal Toxicol 29(7):616–626

    Article  PubMed  CAS  Google Scholar 

  65. Kintz P (2012) Value of the concept of minimal detectable dosage in human hair. Forensic Sci Int 218(1–3):28–30

    Article  PubMed  CAS  Google Scholar 

  66. Anderson DT, Budd RD (2009) Zaleplon (Sonata) analysis in postmortem specimens by gas chromatography-electron capture detection. J Anal Toxicol 33(8):481–485

    Article  PubMed  CAS  Google Scholar 

  67. Levine B, Wu SC, Smialek JE (1999) Zolpidem distribution in postmortem cases. J Forensic Sci 44(2):369–371

    PubMed  CAS  Google Scholar 

  68. Pounder DJ, Davies JI (1994) Zopiclone poisoning: tissue distribution and potential for postmortem diffusion. Forensic Sci Int 65(3):177–183

    Article  PubMed  CAS  Google Scholar 

  69. Zosel A, Osterberg EC, Mycyk MB (2011) Zolpidem misuse with other medications or alcohol frequently results in intensive care unit admission. Am J Ther 18(4):305–308

    Article  PubMed  Google Scholar 

  70. Louis CJ, Fernandez B, Beaumont C et al (2008) A case of zaleplon overdose. Clin Toxicol (Phila) 46(8):782

    Article  Google Scholar 

  71. Kuzniar TJ, Balagani R, Radigan KA et al (2010) Coma with absent brainstem reflexes resulting from zolpidem overdose. Am J Ther 17(5):e172–e174

    Article  PubMed  Google Scholar 

  72. Hamad A, Sharma N (2001) Acute zolpidem overdose leading to coma and respiratory failure. Intensive Care Med 27(7):1239

    Article  PubMed  CAS  Google Scholar 

  73. Lovett B, Watts D, Grossman M (2007) Prolonged coma after eszopiclone overdose. Am J Emerg Med 25(6):735, e735-736

    Article  PubMed  Google Scholar 

  74. Fung HT, Lai CH, Wong OF et al (2008) Two cases of methemoglobinemia following zopiclone ingestion. Clin Toxicol (Phila) 46(2):167–170

    Article  CAS  Google Scholar 

  75. Fung HT, Lai CH, Wong OF et al (2009) Hemolytic anemia after zopiclone overdose. Clin Toxicol (Phila) 47(9):902–903

    Article  CAS  Google Scholar 

  76. Kung SW, Tse ML, Chan YC et al (2008) Zopiclone-associated methemoglobinemia and renal impairment. Clin Toxicol (Phila) 46(10):1099–1100

    Article  Google Scholar 

  77. Kurta DL, Myers LB, Krenzelok EP (1997) Zolpidem (Ambien): a pediatric case series. J Toxicol Clin Toxicol 35(5):453–457

    Article  PubMed  CAS  Google Scholar 

  78. Carbajal R, Blanc P, Paupe A et al (1996) Flumazenil dans les intoxications au Zolpidem chez l'enfant. Arch Ped 3(2):191–192

    Article  CAS  Google Scholar 

  79. Darke S, Deady M, Duflou J (2012) Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001–2010. J Forensic Sci 57(5):1259–1262

    Article  PubMed  Google Scholar 

  80. Buckley NA, McManus PR (2004) Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983–1999). Drug Saf 27(2):135–141

    Article  PubMed  Google Scholar 

  81. Reith DM, Fountain J, McDowell R et al (2003) Comparison of the fatal toxicity index of zopiclone with benzodiazepines. J Toxicol Clin Toxicol 41(7):975–980

    Article  PubMed  CAS  Google Scholar 

  82. Moore KA, Zemrus TL, Ramcharitar V et al (2003) Mixed drug intoxication involving zaleplon (“Sonata”). Forensic Sci Int 134(2–3):120–122

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naren Gunja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gunja, N. The Clinical and Forensic Toxicology of Z-drugs. J. Med. Toxicol. 9, 155–162 (2013). https://doi.org/10.1007/s13181-013-0292-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-013-0292-0

Keywords

Navigation